marijuana stocks news

Cara Therapeutics to Webcast Presentation at the Stifel 2015 Healthcare Conference

Cara Therapeutics, Inc. (CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced that Dr. Derek Chalmers, President and CEO, will present a company overview at the Stifel 2015 Healthcare Conference on Wednesday, November 18, 2015, at 8:45 a.m. ET in New York City.

A live webcast of the presentation can be accessed under “Events and Presentations” in the News & Investors section of the Company’s website at www.CaraTherapeutics.com. An archived webcast recording will be available on the Cara website for approximately 30 days.

About Cara Therapeutics

Cara Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors. Cara is developing a novel and proprietary class of product candidates that target the body’s peripheral nervous system and have demonstrated activity in patients with moderate-to-severe pain without inducing many of the undesirable side effects typically associated with currently available pain therapeutics.

Contact:
INVESTOR CONTACT:
Jesse Baumgartner
Stern Investor Relations, Inc.
212-362-1200
Jesse@sternir.com
MEDIA CONTACT:
Annie Starr
6 Degrees
973-415-8838
astarr@6degreespr.com

MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Neptune Wellness Solutions Inc. (NEPT) Appoints Raymond Silcock as Chief Financial Officer

Neptune Wellness Appoints Raymond Silcock as Chief Financial Officer Neptune Wellness Solutions…

TILT Holdings Inc. (TLLTF) Announces a Proprietary, First-of-its-Kind, Rig-less Dab Solution from Jupiter Research

TILT Holdings Announces a Proprietary, First-of-its-Kind, Rig-less Dab Solution from Jupiter Research…

AbbVie (ABBV) Announces Extension of Review for Supplemental New Drug Application of Upadacitinib

AbbVie Announces Extension of Review for Supplemental New Drug Application of Upadacitinib…

$ERBB Extends Lease; Begins Modification of #Cannabis Cultivation & Extraction Facility

American Green Extends Lease and Begins Modification of Its 12,000 Square Foot…